BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 35551661)

  • 1. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
    Lu K; Chiu KY; Cheng CL
    Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of Immunotherapy in Genitourinary Malignancies.
    Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
    Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Kato M; Uchida J
    Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of immunotherapy in clinical management of genitourinary cancers - a review.
    Mar N; Uchio E; Kalebasty AR
    Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Mori K; Yanagisawa T; Fukuokaya W; Iwatani K; Matsukawa A; Katayama S; Pradere B; Laukhtina E; Rajwa P; Moschini M; Albisinni S; Krajewski W; Cimadamore A; Del Giudice F; Teoh J; Urabe F; Kimura S; Murakami M; Tsuzuki S; Miki J; Miki K; Shariat SF; Kimura T;
    Int J Urol; 2024 Jan; 31(1):25-31. PubMed ID: 37840031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
    Meza L; Malhotra J; Favorito C; Pal SK
    Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
    Marciscano AE; Madan RA
    Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.
    Iacovino ML; Miceli CC; De Felice M; Barone B; Pompella L; Chiancone F; Di Zazzo E; Tirino G; Della Corte CM; Imbimbo C; De Vita F; Crocetto F
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
    Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
    Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunobiology and immunotherapy in genitourinary malignancies.
    Tsiatas M; Grivas P
    Ann Transl Med; 2016 Jul; 4(14):270. PubMed ID: 27563657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.